China smartphone shipments slumped in June on inventory overhang: Jefferies
In recent transactions, Chicago Atlantic Group, LP and its affiliates made significant acquisitions of Vireo Growth Inc. (NASDAQ:VREO) shares, totaling $37,520. The purchases occurred in two separate transactions on March 28 and March 31, 2025, involving the acquisition of 15,900 and 71,600 subordinate voting shares, respectively. The pharmaceutical company, currently valued at approximately $161 million, has shown strong revenue growth of nearly 13% over the last twelve months, with sales reaching $99 million.
The shares were acquired at prices ranging from $0.4255 to $0.4437 per share. Following these transactions, Chicago Atlantic Group and its affiliates collectively hold a substantial number of shares in Vireo Growth, reflecting their continued interest in the company. According to InvestingPro analysis, the company maintains a "GREAT" overall financial health score, despite operating with moderate debt levels. Subscribers can access detailed financial analysis and 12+ additional ProTips for deeper insights into VREO’s performance and outlook.
Chicago Atlantic Group, LP, along with its affiliates such as Chicago Atlantic Credit Opportunities, LLC and Chicago Atlantic Advisers, LLC, are recognized as significant stakeholders in Vireo Growth, each holding over ten percent ownership. The transactions highlight their ongoing strategic investments in the pharmaceutical preparations sector, as represented by Vireo Growth Inc., which maintains a healthy gross profit margin of 51% and a current ratio of 1.7.
In other recent news, Vireo Growth Inc. reported a 15.4% increase in full-year revenue, reaching $99.4 million, while the fourth-quarter revenue rose by 3.5% to $25 million. Despite these revenue gains, the company experienced a net loss of $15.7 million in the fourth quarter, attributed to one-time transaction expenses. Vireo Growth’s future outlook includes strategic initiatives such as the completion of a new cultivation facility and the expansion into adult-use sales in Minnesota, which are expected to drive growth in 2025. Additionally, the company is focusing on capital deployment in New York and Minnesota, with significant contributions anticipated from its New York facility in the second quarter of 2025. The company maintains a strong cash position, ending the year with $91.6 million in cash. Analyst feedback from firms such as Craig Hallum Capital Group highlighted the company’s ongoing efforts to improve flower quality and expand production capacity. These developments reflect Vireo Growth’s strategic direction and operational focus as it navigates the evolving cannabis market.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.